Compare NECB & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NECB | ATAI |
|---|---|---|
| Founded | 1934 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.4M | 1.4B |
| IPO Year | N/A | 2021 |
| Metric | NECB | ATAI |
|---|---|---|
| Price | $23.24 | $4.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 54.2K | ★ 3.2M |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.21 | N/A |
| Revenue | ★ $102,569,000.00 | $3,018,000.00 |
| Revenue This Year | $1.90 | $943.83 |
| Revenue Next Year | $6.93 | N/A |
| P/E Ratio | $7.19 | ★ N/A |
| Revenue Growth | N/A | ★ 811.78 |
| 52 Week Low | $19.27 | $1.15 |
| 52 Week High | $26.37 | $6.75 |
| Indicator | NECB | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 62.25 | 46.37 |
| Support Level | $22.75 | $3.88 |
| Resistance Level | $24.13 | $4.33 |
| Average True Range (ATR) | 0.63 | 0.24 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 67.51 | 35.44 |
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.